Tender Number 1

Auto-translated from da

Original title: Udbudsnummer 1

Amgros I/S

Published: May 12, 2026

Updated: May 20, 2026

Source: TED - Tenders Electronic Daily (EU)

This tender has been awarded

Awarded to GlaxoSmithKline Pharma A/S — DKK 19,000,000

Browse open Health & Medical tenders in Denmark

About This Opportunity

healthcare supply contract awarded in Denmark: Udbudsnummer 1. By Amgros I/S. Awarded to GlaxoSmithKline Pharma A/S (DKK 19.0M, May 2026).

This is a supplies contract in the health and medical services sector. Located in Denmark, Europe, this opportunity is open to firms and consortiums, with an estimated budget of DKK 6.1 million.

Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.

Description

Original language: da

Udbudsnummeret (delkontrakten) omfatter følgende lægemidler: ATC Kode: J05AG05 · Generisk navn: Rilpivirin · Dispenseringsform: Depotinjektionsvæske · Styrke: 900 mg · Enhedsværdi: 15 mg · Mængde i enheder: 16440. Hvert udbudsnummer anses for en selvstændig delkontrakt og udbydes uafhængigt af de øvrige udbudsnumre. En leverandør kan således vælge at give tilbud på ét, flere eller alle udbudsnumre, og tildeling sker separat for hvert enkelt udbudsnummer. En leverandør kan således tildeles en, flere eller alle delkontrakter. Der henvises til udbudsbetingelserne, herunder om afgivelse af tilbud under de enkelte udbudsnumre. Under betegnelsen "mængde i enheder" ovenfor er angivet et skønnet forbrug af lægemidlerne under udbudsnummeret, men det reelle forbrug kan afvige væsentligt derfra. Dette må leverandørerne påregne. Baggrunden herfor er, at der er tale om lægemidler til patientbehandling på de offentlige sygehuse, hvor patientens behov skal imødekommes. For nærmere beskrivelse henvises der til udbudsbetingelserne og rammeaftalen.

Data provenance

This notice is sourced from TED - Tenders Electronic Daily (EU) and was originally published on May 12, 2026. Last refreshed today. Original language: da. BidsFactory mirrors official procurement notices and links back to the source for full legal text.

About Amgros I/S

Amgros I/S has issued 140 procurement notices on BidsFactory, including 27 currently open and 52 awarded contracts. Activity concentrates in Health & Medical, General Supplies & Services, and Media & Communications. All notices are published for Denmark. Notices are distributed via TED - Tenders Electronic Daily (EU) and Denmark Udbud. Most recent publication: May 20, 2026.

Frequently asked questions about this tender

Who is the contracting authority?

This notice was issued by Amgros I/S in Denmark. The authority is responsible for evaluating bids, awarding the contract, and managing performance.

What type of contract is this?

This is a Supplies contract in the Health & Medical sector. The classification helps bidders match the opportunity to their qualifications and registered scope of supply.

How much was the contract awarded for?

GlaxoSmithKline Pharma A/S was awarded the contract for DKK 19,000,000. The figure reflects the value disclosed by the contracting authority in the award notice.

Where will the contract be performed?

The contract is for delivery in Denmark. Foreign bidders should review local registration, taxation, and any in-country presence requirements before submitting.

How can I submit a bid?

Visit TED - Tenders Electronic Daily (EU) to access the full notice, required documents, and submission instructions provided by the contracting authority.

Is this tender still open?

No — the contract has already been awarded to GlaxoSmithKline Pharma A/S. The award notice is archived on BidsFactory for transparency and market intelligence.